Change in control at Novartis India; ChrysCapital completes takeover

Acquisition announcedOpen offerStrategic Transactions View source PDF Explain this filing

NOVARTIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹1600.00

prior close

₹1610.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-0.4% vs market

Pharmaceuticals peers, median of 162sector-0.7%-0.3% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-0.2

15m

-0.5

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0-0.6-0.4-0.7-0.3

Next day

-2.4+0.5-2.9-0.5-1.9

+2.8+1.9+0.9+0.2+2.6

+1.8+2.3-0.5+0.1+1.7

+2.3+3.6-1.4+0.5+1.8

-0.1+4.0-4.1+0.7-0.8

+0.2+4.0-3.7+1.4-1.2

15d

-7.3+4.9-12.2+0.4-7.7

-1.6+5.9-7.5+1.7-3.3

+19.7+4.8+14.9+2.7+17.0

+7.8-4.6+12.4-3.1+10.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Novartis AG has sold its 1.74 crore equity shares (controlling stake) in Novartis India to ChrysCapital-backed entities (WaveRise, ChrysCapital Fund X and Two Infinity Partners). The open offer has concluded and WaveRise and Fund X have acquired control. Novartis AG is reclassified from promoter to public. Board reconstituted with new directors appointed and several existing directors resigning.

Likely market impact

Major ownership change. ChrysCapital entities now control Novartis India. Expect strategic shifts as private equity takes charge of the pharma business.